175 related articles for article (PubMed ID: 36090630)
1. Prognostic implications of cellular senescence in resected non-small cell lung cancer.
Domen A; Deben C; De Pauw I; Hermans C; Lambrechts H; Verswyvel J; Siozopoulou V; Pauwels P; Demaria M; van de Wiel M; Janssens A; Hendriks JMH; Van Schil P; Vermorken JB; Vandamme T; Prenen H; Peeters M; Lardon F; Wouters A
Transl Lung Cancer Res; 2022 Aug; 11(8):1526-1539. PubMed ID: 36090630
[TBL] [Abstract][Full Text] [Related]
2. The Prognostic Role of PORT and EGFR Mutation Status in Completely Resected Stage IIIA/N2 Non-Small Cell Lung Cancer Patients with Postoperative Chemotherapy.
Yang H; Wang K; Li S; Li Y; Yuan L
Pathol Oncol Res; 2021; 27():1609898. PubMed ID: 34447289
[No Abstract] [Full Text] [Related]
3. Combination of PD-L1 expression and NLR as prognostic marker in patients with surgically resected non-small cell lung cancer.
Wang X; Cao L; Li S; Wang F; Huang D; Jiang R
J Cancer; 2019; 10(26):6703-6710. PubMed ID: 31777599
[No Abstract] [Full Text] [Related]
4. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
[TBL] [Abstract][Full Text] [Related]
5. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of EGFR mutations in surgically resected pathological stage I lung adenocarcinoma.
Nishii T; Yokose T; Miyagi Y; Daigo Y; Isaka T; Furumoto H; Ito H; Murakami S; Kondo T; Saito H; Oshita F; Yamada K; Matsukuma S; Nakayama H; Masuda M
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e204-e211. PubMed ID: 27349355
[TBL] [Abstract][Full Text] [Related]
7. Treatment of clinical T4 stage superior sulcus non-small cell lung cancer: a propensity-matched analysis of the surveillance, epidemiology, and end results database.
Wen J; Liu D; Chen D; Chen J; Xu X; Chen C; Zhang F; Duan S; Zhu R; Fan M; Chen Y
Biosci Rep; 2019 Feb; 39(2):. PubMed ID: 30647107
[No Abstract] [Full Text] [Related]
8. Detection of epidermal growth factor receptor (
Guo K; Shao C; Han L; Liu H; Ma Z; Yang Y; Feng Y; Pan M; Santarpia M; Carmo-Fonseca M; Silveira C; Lee KY; Han J; Li X; Yan X
Transl Lung Cancer Res; 2021 Jul; 10(7):3213-3225. PubMed ID: 34430359
[TBL] [Abstract][Full Text] [Related]
9. Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients.
Yuan A; Yu CJ; Shun CT; Luh KT; Kuo SH; Lee YC; Yang PC
Int J Cancer; 2005 Jul; 115(4):545-55. PubMed ID: 15704107
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of senescence markers p14(ARF) and p16(INK4a) in breast cancer is associated with an increased risk of disease recurrence and poor survival outcome.
Pare R; Shin JS; Lee CS
Histopathology; 2016 Sep; 69(3):479-91. PubMed ID: 26843058
[TBL] [Abstract][Full Text] [Related]
11. Effect of epidermal growth factor receptor mutation on early-stage non-small cell lung cancer according to the 8th TNM classification.
Isaka T; Ito H; Nakayama H; Yokose T; Yamada K; Masuda M
Lung Cancer; 2020 Jul; 145():111-118. PubMed ID: 32428800
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of filamin-A protein is associated with aggressive phenotype and poor survival outcomes in NSCLC patients treated with platinum-based combination chemotherapy.
Gachechiladze M; Skarda J; Janikova M; Mgebrishvili G; Kharaishvili G; Kolek V; Grygarkova I; Klein J; Poprachova A; Arabuli M; Kolar Z
Neoplasma; 2016; 63(2):274-81. PubMed ID: 26774150
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors after complete resection of pN2 non-small cell lung cancer.
Sonobe M; Date H; Wada H; Okubo K; Hamakawa H; Teramukai S; Matsumura A; Nakagawa T; Sumitomo S; Miyamoto Y; Okumura N; Takeo S; Kawakami K; Aoki M; Kosaka S;
J Thorac Cardiovasc Surg; 2013 Oct; 146(4):788-95. PubMed ID: 23810113
[TBL] [Abstract][Full Text] [Related]
14. Patterns and risks of postoperative recurrence in completely resected EGFR-mutant non-small cell lung cancer: prognostic significance of routine immunohistochemical markers.
Ni J; Guo T; Li Y; Yang X; Li Y; Zou L; Chu L; Chu X; Li S; Ye L; Zhang Y; Zhu Z
Transl Lung Cancer Res; 2019 Dec; 8(6):967-978. PubMed ID: 32010575
[TBL] [Abstract][Full Text] [Related]
15. The preoperative hemoglobin, albumin, lymphocyte, and platelet score is a prognostic factor for non-small cell lung cancer patients undergoing adjuvant chemotherapy: a retrospective study.
Wei S; Shao J; Wang J; Wang G
Ann Transl Med; 2022 Apr; 10(8):457. PubMed ID: 35571436
[TBL] [Abstract][Full Text] [Related]
16. Effect of epidermal growth factor receptor gene mutation on the prognosis of pathological stage II-IIIA (8th edition TNM classification) primary lung cancer after curative surgery.
Isaka T; Ito H; Nakayama H; Yokose T; Saito H; Adachi H; Miura J; Shigefuku S; Kikuchi A; Rino Y
Lung Cancer; 2021 Dec; 162():128-134. PubMed ID: 34775216
[TBL] [Abstract][Full Text] [Related]
17. Development and Validation of an Immune-Based Prognostic Risk Score for Patients With Resected Non-Small Cell Lung Cancer.
He L; Huang Y; Chen X; Huang X; Wang H; Zhang Y; Liang C; Li Z; Yan L; Liu Z
Front Immunol; 2022; 13():835630. PubMed ID: 35401554
[TBL] [Abstract][Full Text] [Related]
18. Topoisomerase II alpha expression and the benefit of adjuvant chemotherapy for postoperative patients with non-small cell lung cancer.
Yan S; Shun-Chang J; Li C; Jie L; Ya-Li L; Ling-Xiong W
BMC Cancer; 2010 Nov; 10():621. PubMed ID: 21067592
[TBL] [Abstract][Full Text] [Related]
19. Systemic inflammation, nutritional status and tumor immune microenvironment determine outcome of resected non-small cell lung cancer.
Alifano M; Mansuet-Lupo A; Lococo F; Roche N; Bobbio A; Canny E; Schussler O; Dermine H; Régnard JF; Burroni B; Goc J; Biton J; Ouakrim H; Cremer I; Dieu-Nosjean MC; Damotte D
PLoS One; 2014; 9(9):e106914. PubMed ID: 25238252
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials.
Zhao P; Zhen H; Zhao H; Zhao L; Cao B
BMC Cancer; 2022 Mar; 22(1):328. PubMed ID: 35346117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
